Processa Pharmaceuticals (PCSA) Net Cash Flow (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported Net Cash Flow for 15 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 136.77% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2026 stood at -$5.9 million (down 531.42% YoY), and the FY2025 full-year result was $4.3 million, up 223.21% from the prior year.
• Net Cash Flow climbed to -$1.5 million in Q2 2026 per PCSA's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $4.2 million in Q1 2023 and bottomed at -$3.9 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$858891.2 across 5 years, with a median of -$1.9 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow surged 301.53% in 2023, then slumped 326.01% in 2026.
• Over 5 years, Net Cash Flow stood at -$2.6 million in 2022, then advanced by 15.54% to -$2.2 million in 2023, then climbed by 21.09% to -$1.7 million in 2024, then soared by 104.65% to $79113.0 in 2025, then sank by 1977.58% to -$1.5 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.5 million, -$3.9 million, and $79113.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.